JTI Reports 10.7% Net Income Growth in Q2 2022

Jul.30.2022
JTI Reports 10.7% Net Income Growth in Q2 2022
JTI Group reports a strong performance with net income of 1.27 trillion yen ($95 billion) in Q2 2022.

The JTI Group has reported a net income of JPY 1.27 trillion (USD 9.5 billion) for the second quarter of 2022, reflecting a year-on-year growth of 10.7% compared to 2021. When calculated at a fixed exchange rate, the income growth reached 3.7%, which totaled JPY 1.14 trillion. The adjusted operating profit increased by 8% at a fixed currency rate, reaching JPY 338.77 billion. The profit also increased by 17.3% to JPY 264.1 billion.


There is no context or information provided to translate into standard journalistic English. Please provide more details or a sentence for context.


Masamichi Terabatake, President and CEO of JTI Group, announced that the company's performance in the first half of the year was strong, largely driven by advantageous product pricing. He also expressed encouragement with the performance of Ploom X and stated that the company will take advantage of Japan's expertise to guide the international release of the product in the second half of this year.


As a result of favorable fluctuations in the Chinese yuan against the Japanese yen, we have revised upwards our adjusted operating profit and profit forecasts for full-year 2022. However, taking into account the higher input costs that are affecting our supply chain operations, the constant currency-adjusted operating profit is down. The guidance for full-year dividend per share remains unchanged at 150 yen per share. The interim dividend is 75 yen per share.


Regarding Russia, despite continuing to manufacture and distribute our products in compliance with national and international sanctions, the operating environment is becoming increasingly complex. In this context, the JTI group continues to evaluate various options for its Russian business, including the possibility of transferring ownership, and will make necessary decisions in accordance with the group's management principles to address the constantly changing situation.


Please provide the text that needs to be translated.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

AIRSCREAM Solidifies South African Leadership & Championing Truth in Vaping
AIRSCREAM Solidifies South African Leadership & Championing Truth in Vaping
As South Africa’s leading lifestyle vaping brand, AIRSCREAM is accelerating its regional growth strategy with the launch of its bold new initiative, “Trust ML, Not Puff.” The campaign calls for factual, millilitre (ml)-based transparency across the vaping industry, directly confronting misleading puff-count marketing practices and promoting clear, standardised information that reflects the true value and capacity of vaping products.
Nov.28
VCU Tests Nearly 1,300 School-Confiscated Vapes, Finding Mislabeling, Mixed Cannabinoids and Contamination
VCU Tests Nearly 1,300 School-Confiscated Vapes, Finding Mislabeling, Mixed Cannabinoids and Contamination
New research from Virginia Commonwealth University (VCU) found microbial contamination — including coliform, a bacteria indicating fecal exposure — in some vaping devices confiscated from U.S. schools. However, researchers stressed that newly purchased, unopened vapes showed no such contamination. The findings point to risks linked to unregulated products and improper storage conditions, reinforcing the importance of regulated supply chains and product authentication.
News
Dec.01
PMI AI White Paper Warns of “Cognitive Atrophy” and Attention Erosion, Calls for Focus on Human Cognition’s Evolution
PMI AI White Paper Warns of “Cognitive Atrophy” and Attention Erosion, Calls for Focus on Human Cognition’s Evolution
Philip Morris International (PMI) has released a white paper calling for cross-sector dialogue on how AI may affect human cognitive abilities. The paper flags risks including “cognitive atrophy” and attention erosion, and warns of a widening cognitive divide and rising pressures on information verification and trust.
Jan.21 by 2FIRSTS.ai
Pakistan Speeds Up Local Nicotine Pouch Production as PMI Unit Prepares to Launch ZYN
Pakistan Speeds Up Local Nicotine Pouch Production as PMI Unit Prepares to Launch ZYN
Pakistan’s smokeless, tobacco-free nicotine pouch market has expanded rapidly in recent years, prompting major tobacco companies to accelerate local investments, with Philip Morris Pakistan Ltd. (PMPKL) set to produce ZYN at its Sahiwal facility.
Dec.05 by 2FIRSTS.ai
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
As regulation tightens and innovation matures, competition in the new tobacco industry is shifting. In its 2026 Global Product Trends in the New Tobacco Industry report, 2Firsts examines how heated tobacco, nicotine pouches, and vape products are moving beyond feature-driven upgrades toward system-level design, where experience management, compliance structure, and engineering capability increasingly shape long-term competition.
Jan.13 by 2Firsts Perspectives
Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai